Rapid Onset of Response and Patient-reportedOutcomes After OnabotulinumtoxinA Treatmentof Moderate-to-Severe Glabellar Lines

January 2011 | Volume 10 | Issue 1 | Original Article | 39 | Copyright © 2011

Kenneth R. Beer MD, Charles Boyd MD, Rina K. Patel MS, Beta Bowen MS, Steven P. James MD, Mitchell F. Brin MD

Abstract

Introduction: No previously published botulinum toxin type A cosmetic trials included both physician and subject measures of onset. Objective: Determine physician- and subject-reported onset of onabotulinumtoxinA. Methods: Two-center open-label, 14-day study in toxin-naive female patients with moderate-to-severe glabellar lines (GL) treated with 20-U onabotulinumtoxinA. Onset endpoint was categorical (physician assessed: days 2, 3, 4, 7 and 14; subject: 14-day diary). Subjects rated improvements in GL severity and completed the Facial Line Outcomes (FLO) and Self-Perception of Age (SPA) questionnaires. Results: Nearly half, 48 percent (n=45) of subjects, reported onset by day 1. Subject- and physician-reported onset rates, respectively, were 77 percent and 87 percent (day 2), 93 percent and 91 percent (day 3), 98 percent and 100 percent (day 4), and 100 percent thereafter. At all time points, FLO and SPA improved (P≤0.008 and P≤0.01, respectively). No serious adverse events occurred. Conclusion: OnabotulinumtoxinA provides rapid onset (one to two days) based on physician and subject assessment. (J Drugs Dermatol. 2011;10[1]:39-44.)

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Related Articles